HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
OMG
oligodendrocyte myelin glycoprotein
Chromosome 17 · 17q11.2
NCBI Gene: 4974Ensembl: ENSG00000126861.5HGNC: HGNC:8135UniProt: P23515
29PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
neuron projection regenerationplasma membranerisk-taking behavioursmoking initiationneurofibromatosis type 1osteoarthritis, hip
✦AI Summary

OMG (oligodendrocyte myelin glycoprotein) is a brain-specific cell adhesion molecule that functions as a determinant of neurodegenerative resiliency 1. Mechanistically, OMG contributes to the interactive processes required for myelination in the central nervous system [UniProt annotation] and maintains axonal structural integrity 1. Lower circulating OMG levels are associated with cortical amyloid deposition, compromised brain structure, and dementia diagnosis 1. Prospectively, reduced plasma OMG predicts cognitive decline over 7-20 year follow-up periods, with two-sample Mendelian randomization analyses supporting OMG as causally protective against multiple neurodegenerative diseases including Alzheimer's disease and related dementias 1. Additionally, lower OMG levels are detected in multiple sclerosis, another neurodegenerative condition 1. Clinically, peripheral blood OMG abundance reliably captures neuroprotective mechanisms and represents a promising biomarker for neurodegenerative disease risk stratification in older adults 1. These findings position OMG as a mechanistically relevant protein bridging myelination biology with neurodegeneration, though therapeutic applications remain to be developed.

Sources cited
1
OMG is brain-specific protein implicated in myelination, associated with amyloid deposition, dementia, and acts as determinant of neurodegenerative resiliency; lower levels predict cognitive decline and are causally protective against neurodegenerative diseases
PMID: 41491993
⚠Limited data available — This gene has 1 indexed publication. Summary and analysis may be incomplete.
Disease Associationsⓘ20
risk-taking behaviourOpen Targets
0.39Weak
smoking initiationOpen Targets
0.36Weak
neurofibromatosis type 1Open Targets
0.34Weak
osteoarthritis, hipOpen Targets
0.19Weak
total hip arthroplastyOpen Targets
0.18Weak
osteoarthritisOpen Targets
0.16Weak
Abnormality of the skeletal systemOpen Targets
0.12Weak
spinal stenosisOpen Targets
0.09Suggestive
type 2 diabetes mellitusOpen Targets
0.08Suggestive
substance-related disorderOpen Targets
0.06Suggestive
medulloblastomaOpen Targets
0.05Suggestive
encephalitisOpen Targets
0.05Suggestive
atypical teratoid rhabdoid tumorOpen Targets
0.05Suggestive
breast carcinomaOpen Targets
0.04Suggestive
optic neuritisOpen Targets
0.03Suggestive
pancreatic adenocarcinomaOpen Targets
0.03Suggestive
osteoarthritis, kneeOpen Targets
0.03Suggestive
childhood supratentorial ependymomaOpen Targets
0.03Suggestive
experimental autoimmune encephalomyelitisOpen Targets
0.03Suggestive
type 1 diabetes mellitusOpen Targets
0.03Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
RTN4Protein interaction100%LINGO1Protein interaction100%TNFRSF19Protein interaction99%MAGProtein interaction99%NGFRProtein interaction99%RTN4RProtein interaction99%
Tissue Expression6 tissues
Brain
100%
Bone Marrow
7%
Lung
5%
Liver
1%
Ovary
1%
Heart
0%
Gene Interaction Network
Click a node to explore
OMGRTN4LINGO1TNFRSF19MAGNGFRRTN4R
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt P23515
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.56Moderately Constrained
pLIⓘ
0.90Intermediate
Observed/Expected LoF0.32 [0.19–0.56]
RankingsWhere OMG stands among ~20K protein-coding genes
  • #12,195of 20,598
    Most Researched29
  • #3,700of 17,882
    Most Constrained (LOEUF)0.56 · top quartile
Genes detectedOMG
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Development and Validation of the American Heart Association's PREVENT Equations.
PMID: 37947085
Circulation · 2024
1.00
2
Myasthenia gravis: MuSK MG, late-onset MG and ocular MG.
PMID: 33458590
Acta Myol · 2020
0.90
3
Recommendations for the management of myasthenia gravis in Belgium.
PMID: 38649556
Acta Neurol Belg · 2024
0.80
4
Use of Short Peripheral Intravenous Catheters: Characteristics, Management, and Outcomes Worldwide.
PMID: 29813140
J Hosp Med · 2018
0.70
5
OMG! A proteomic determinant of neurodegenerative resiliency.
PMID: 41491993
Mol Neurodegener · 2026
0.60